{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T11:36:55Z","timestamp":1775734615141,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"DOI":"10.1007\/s00270-025-04113-8","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T16:52:24Z","timestamp":1752166344000},"page":"1113-1125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tumor Dose as an Oncologic Predictor of Outcome in Patients with HCC Treated with Resin Y90 Microspheres"],"prefix":"10.1007","volume":"48","author":[{"given":"Howard","family":"Dabbous","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Gad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mohnasky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Villalobos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Brandon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minzhi","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4569-2720","authenticated-orcid":false,"given":"Nima","family":"Kokabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"4113_CR1","doi-asserted-by":"publisher","first-page":"S361","DOI":"10.21037\/jgo.2020.02.08","volume":"12","author":"H Samant","year":"2021","unstructured":"Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol. 2021;12:S361\u201373. https:\/\/doi.org\/10.21037\/jgo.2020.02.08.","journal-title":"J Gastrointest Oncol"},{"key":"4113_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/hep.27443","volume":"61","author":"EG Giannini","year":"2015","unstructured":"Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Benvegn\u00f9 L, Caturelli E, Zoli M, Borzio F, Chiaramonte M, Trevisani F. Prognosis of untreated hepatocellular carcinoma. Hepatol Baltim Md. 2015;61:184\u201390. https:\/\/doi.org\/10.1002\/hep.27443.","journal-title":"Hepatol Baltim Md"},{"key":"4113_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","journal-title":"J Hepatol"},{"key":"4113_CR4","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","volume":"49","author":"M Lam","year":"2022","unstructured":"Lam M, Garin E, Maccauro M, Kappadath SC, Sze DY, Turkmen C, Cantasdemir M, Haste P, Herrmann K, Alsuhaibani HS, Dreher M, Fowers KD, Salem R. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging. 2022;49:3340\u201352. https:\/\/doi.org\/10.1007\/s00259-022-05774-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4113_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, Assenat E, Tacher V, Robert C, Terroir-Cassou-Mounat M, Costentin CE, Milliner M. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial, Lancet. Gastroenterol Hepatol. 2021;6:17\u201329. https:\/\/doi.org\/10.1016\/S2468-1253(20)30290-9.","journal-title":"Gastroenterol Hepatol"},{"issue":"1","key":"4113_CR6","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.2217\/fon-2019-0658","volume":"16","author":"DH Palmer","year":"2019","unstructured":"Palmer DH, Hawkins NS, Vilgrain V, Pereira H, Chatellier G, Ross PJ. Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study. Future Oncol. 2019;16(1):4315\u201325. https:\/\/doi.org\/10.2217\/fon-2019-0658.","journal-title":"Future Oncol"},{"key":"4113_CR7","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.2967\/jnumed.110.075861","volume":"51","author":"L Strigari","year":"2010","unstructured":"Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A, Iaccarino G, Benassi M, Ettorre GM, Maini CL. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med Off Publ Soc Nucl Med. 2010;51:1377\u201385. https:\/\/doi.org\/10.2967\/jnumed.110.075861.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"4113_CR8","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1007\/s00259-023-06111-9","volume":"50","author":"N Kokabi","year":"2023","unstructured":"Kokabi N, Arndt-Webster L, Chen B, Brandon D, Sethi I, Davarpanahfakhr A, Galt J, Elsayed M, Bercu Z, Cristescu M, Kappadath SC, Schuster DM. Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study. Eur J Nucl Med Mol Imaging. 2023;50:1743\u201352. https:\/\/doi.org\/10.1007\/s00259-023-06111-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4113_CR9","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/RLU.0000000000005198","volume":"49","author":"N Kokabi","year":"2024","unstructured":"Kokabi N, Webster LA, Dabbous H, Shah A, Brandon D, Galt J, Xing M, Villalobos A, Davarpanahfakhr A, Kappadath SC, Schuster DM. Resin-based 90 Y tumor dose as a predictor of duration of response and survival in patients with surgically unresectable hepatocellular carcinoma: a prospective single-arm study. Clin Nucl Med. 2024;49:799\u2013805. https:\/\/doi.org\/10.1097\/RLU.0000000000005198.","journal-title":"Clin Nucl Med"},{"key":"4113_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100633","author":"F Kolligs","year":"2023","unstructured":"Kolligs F, Arnold D, Golfieri R, Pech M, Peynircioglu B, Pfammatter T, Ronot M, Sangro B, Schaefer N, Maleux G, Schmid A, Vit A. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: results from the prospective CIRT study. JHEP Rep. 2023. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100633.","journal-title":"JHEP Rep."},{"key":"4113_CR11","unstructured":"Health USDo, Human S. National institutes of H, et al. Common Terminology criteria for adverse events (CTCAE) version 5.0. Bethesda, MD: US Department of Health and Human Services; 2017."},{"key":"4113_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.tvir.2019.02.006","volume":"22","author":"E Wehrenberg-Klee","year":"2019","unstructured":"Wehrenberg-Klee E, Gandhi RT, Ganguli S. Patient selection and clinical outcomes of Y90 in hepatocellular carcinoma. Tech Vasc Interv Radiol. 2019;22:70\u20133. https:\/\/doi.org\/10.1053\/j.tvir.2019.02.006.","journal-title":"Tech Vasc Interv Radiol"},{"key":"4113_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1055\/s-0043-1778659","volume":"41","author":"MK Fassia","year":"2024","unstructured":"Fassia MK, Charalel RA. Techniques to optimize radioembolization tumor coverage. Semin Interv Radiol. 2024;41:16\u20139. https:\/\/doi.org\/10.1055\/s-0043-1778659.","journal-title":"Semin Interv Radiol"},{"key":"4113_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1055\/s-0044-1779715","volume":"41","author":"A Villalobos","year":"2024","unstructured":"Villalobos A, du Pisanie JL, Gandhi RT, Kokabi N. Yttrium-90 radioembolization dosimetry: dose considerations, optimization, and tips. Semin Interv Radiol. 2024;41:63\u201378. https:\/\/doi.org\/10.1055\/s-0044-1779715.","journal-title":"Semin Interv Radiol"},{"key":"4113_CR15","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.jvir.2023.02.030","volume":"34","author":"A Villalobos","year":"2023","unstructured":"Villalobos A, Arndt L, Cheng B, Dabbous H, Loya M, Majdalany B, Bercu Z, Kokabi N. Yttrium-90 radiation segmentectomy of hepatocellular carcinoma: a comparative study of the effectiveness, safety, and dosimetry of glass-based versus resin-based microspheres. J Vasc Interv Radiol. 2023;34:1226\u201334. https:\/\/doi.org\/10.1016\/j.jvir.2023.02.030.","journal-title":"J Vasc Interv Radiol"},{"key":"4113_CR16","doi-asserted-by":"publisher","first-page":"e55742","DOI":"10.1371\/journal.pone.0055742","volume":"8","author":"M Elschot","year":"2013","unstructured":"Elschot M, Vermolen BJ, Lam MGEH, de Keizer B, van den bosch MAAJ, de Jong HWAM. Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization. PloS One. 2013;8:e55742. https:\/\/doi.org\/10.1371\/journal.pone.0055742.","journal-title":"PloS One"},{"key":"4113_CR17","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1007\/s00259-021-05188-4","volume":"48","author":"H Duan","year":"2021","unstructured":"Duan H, Khalaf MH, Ferri V, Baratto L, Srinivas SM, Sze DY, Iagaru A. High quality imaging and dosimetry for yttrium-90 ((90)Y) liver radioembolization using a SiPM-based PET\/CT scanner. Eur J Nucl Med Mol Imaging. 2021;48:2426\u201336. https:\/\/doi.org\/10.1007\/s00259-021-05188-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4113_CR18","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1148\/radiol.2020191606","volume":"296","author":"A-L Hermann","year":"2020","unstructured":"Hermann A-L, Dieudonn\u00e9 A, Ronot M, Sanchez M, Pereira H, Chatellier G, Garin E, Castera L, Lebtahi R, Vilgrain V. Relationship of tumor radiation\u2013absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90Y in the SARAH study. Radiology. 2020;296:673\u201384. https:\/\/doi.org\/10.1148\/radiol.2020191606.","journal-title":"Radiology"},{"key":"4113_CR19","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s00259-013-2674-6","volume":"41","author":"C Spreafico","year":"2014","unstructured":"Spreafico C, Maccauro M, Mazzaferro V, Chiesa C. The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE). Eur J Nucl Med Mol Imaging. 2014;41:634\u20138. https:\/\/doi.org\/10.1007\/s00259-013-2674-6.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-025-04113-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-025-04113-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-025-04113-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T17:55:32Z","timestamp":1754416532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-025-04113-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":19,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["4113"],"URL":"https:\/\/doi.org\/10.1007\/s00270-025-04113-8","relation":{},"ISSN":["1432-086X"],"issn-type":[{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NK is a consultant for Sirtex and Boston Scientific.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study has obtained IRB approval from Emory University and the need for informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Consent for publication was obtained for every individual person\u2019s data included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}